KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ClearPoint Neuro (CLPT) Shares Outstanding (2018 - 2025)

ClearPoint Neuro (CLPT) has disclosed Shares Outstanding for 13 consecutive years, with $29.4 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 6.34% to $29.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $29.4 million through Dec 2025, up 6.34% year-over-year, with the annual reading at $29.4 million for FY2025, 6.34% up from the prior year.
  • Shares Outstanding hit $29.4 million in Q4 2025 for ClearPoint Neuro, up from $28.4 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $29.4 million in Q4 2025 to a low of $20.7 million in Q1 2021.
  • Historically, Shares Outstanding has averaged $25.3 million across 5 years, with a median of $24.6 million in 2023.
  • Biggest five-year swings in Shares Outstanding: soared 43.91% in 2021 and later grew 0.3% in 2023.
  • Year by year, Shares Outstanding stood at $23.7 million in 2021, then increased by 3.86% to $24.6 million in 2022, then grew by 0.3% to $24.7 million in 2023, then increased by 12.03% to $27.6 million in 2024, then rose by 6.34% to $29.4 million in 2025.
  • Business Quant data shows Shares Outstanding for CLPT at $29.4 million in Q4 2025, $28.4 million in Q3 2025, and $28.0 million in Q1 2025.